Jt What interests my wife and I the most is the 34% reduction in the risk of secondary Patency loss over 1 yr compared to placebo . Thats really clinically important to her ....34% reduction in loss of Patency .
What concerns me the most tho is the P value of this data 0.048
The only difference between the first P3 and this final P3 ( besides the endpts ) is that they have recruited 600 patients instead of 300.
Is that enough to see a significant improvement in the P value ....and excuse my biostatistics ignorance but how exactly does that work ? Thx Kiwi
News 
Market Data 
Discover 
